INSM - Insmed Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
14%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 30.34%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -264.83%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 4.63
Debt Ratio is 0.6
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.23
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Insmed Inc (INSM) - http://www.insmed.com/
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - William Lewis
Employees - 778
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2026 and future.
Know the Stock © 2026 and future.